Codeine

Codeine

SCHEMBL3031563

COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341.O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRD1OPRK1OPRM1

The experimentally established mechanism targets of Codeine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
OPRM1 known ✓ P35372 7/20 1.00
OPRD1 known ✓ P41143 9/20 0.98
OPRK1 known ✓ P41145 5/20 0.98
MRGPRX2 Q96LB1 4/20 0.98
ADRB1 P08588 1/20 0.98
PDE4D Q08499 1/20 0.98
PDE3A Q14432 1/20 0.98
SLC22A1 O15245 1/20 0.74
ADRA2A P08913 1/20 0.74
ARRB1 P49407 1/20 0.74
SLC18A3 Q16572 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Codeine SCHEMBL29938690 1.00 OPRM1 (1.00) OPRM1OPRD1OPRK1MRGPRX2ADRB1
Codeine SCHEMBL7632902 1.00 OPRM1 (1.00) OPRM1OPRD1OPRK1MRGPRX2ADRB1
Codeine SCHEMBL9324126 0.99 OPRM1 (0.98) OPRM1OPRD1OPRK1MRGPRX2ADRB1
Codeine SCHEMBL8218174 0.99 OPRD1 (1.00) OPRM1OPRD1OPRK1MRGPRX2ADRB1
Codeine SCHEMBL10329428 0.99 OPRD1 (1.00) OPRM1OPRD1OPRK1MRGPRX2ADRB1
Codeine SCHEMBL13696342 0.99 OPRD1 (1.00) OPRM1OPRD1OPRK1MRGPRX2ADRB1
Codeine SCHEMBL1560699 0.99 OPRD1 (1.00) OPRM1OPRD1OPRK1MRGPRX2ADRB1
Codeine SCHEMBL16922140 0.99 OPRD1 (1.00) OPRM1OPRD1OPRK1MRGPRX2ADRB1
Codeine SCHEMBL21077535 0.99 OPRD1 (1.00) OPRM1OPRD1OPRK1MRGPRX2ADRB1
Codeine SCHEMBL14371354 0.99 OPRD1 (1.00) OPRM1OPRD1OPRK1MRGPRX2ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230001128-A1 AEROSOLIZATION SYSTEMS, METHODS, AND APPARATUSES SHUSTER GARY STEPHEN (CA) 2023-01-05 US disclosed
US-20150133664-A1 CHEMICAL TRANSFORMATIONS OF (-)-CODEINE TO AFFORD DERIVATIVES OF CODEINE AND MORPHINE THEREOF UNIV TEXAS (US) 2015-05-14 US disclosed
WO-2013184902-A1 CHEMICAL TRANSFORMATIONS OF (-)-CODEINE TO AFFORD DERIVATIVES OF CODEINE AND MORPHINE THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-12-12 WO disclosed
US-8450365-B2 Efficient synthesis of galanthamine BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-05-28 US disclosed
US-8362283-B2 Cross-conjugated 2,5-cyclohexadienone and related synthesis methods BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-01-29 US disclosed
CN-102813654-A Matrix for sustained, invariant and independent release of active compounds EURO CELTIQUE SA 2012-12-12 CN disclosed
US-8293927-B2 Efficient synthesis of morphine and codeine BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-10-23 US disclosed
CN-1646102-B Pharmaceutical preparation containing oxycodone and naloxone EURO CELTIQUE SA 2012-08-15 CN disclosed
CN-102387704-A Agonists and antagonists of the S1P5 receptor, and methods of uses thereof ABBOTT LAB 2012-03-21 CN disclosed
EP-2395835-A1 AGONISTS AND ANTAGONISTS OF THE SIP5 RECEPTOR, AND METHODS OF USES THEREOF Abbott Laboratories (US) 2011-12-21 EP disclosed
WO-2010132570-A1 SYNTHESIS OF MORPHINE AND RELATED DERIVATIVES BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) 2010-11-18 WO disclosed
US-20100292475-A1 Efficient Synthesis Of Morphine And Codeine BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM 2010-11-18 US disclosed
US-20100228032-A1 Process for Making Apomorphine and Apocodeine MALLINCKRODT INC. 2010-09-09 US disclosed
US-20100216998-A1 Facile \"One Pot' Process for Apomorphine From Codeine MALLINCKRODT INC. (US) 2010-08-26 US disclosed
US-20100216762-A1 Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof ABBOTT LABORATORIES (US) 2010-08-26 US disclosed
WO-2010093704-A1 AGONISTS AND ANTAGONISTS OF THE S1P5 RECEPTOR, AND METHODS OF USES THEREOF ABBOTT LABORATORIES (US) 2010-08-19 WO disclosed
EP-2190818-A1 FACILE 'ONE POT' PROCESS FOR APOMORPHINE FROM CODEINE Mallinckrodt Inc. (US) 2010-06-02 EP disclosed
WO-2009038958-A1 FACILE 'ONE POT' PROCESS FOR APOMORPHINE FROM CODEINE MALLINCKRODT INC. (US) 2009-03-26 WO disclosed
EP-2007730-A1 PROCESS FOR MAKING APOMORPHINE AND APOCODEINE Mallinckrodt, Inc. (US) 2008-12-31 EP disclosed
WO-2007126659-A1 PROCESS FOR MAKING APOMORPHINE AND APOCODEINE MALLINCKRODT INC. (US) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228032-A1 Process for Making Apomorphine and Apocodeine OPRK1, OPRM1, OPRD1 OPRM1 2/4885OPRD1 3/4885OPRK1 1/4885
US-20100216998-A1 Facile \"One Pot' Process for Apomorphine From Codeine OPRM1, OPRK1, OPRD1 OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885
US-20100216762-A1 Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof S1PR5, LPAR5, S1PR1 OPRM1 209/4885OPRD1 215/4885OPRK1 72/4885
US-20100292475-A1 Efficient Synthesis Of Morphine And Codeine OPRK1, OPRM1, OPRL1 OPRM1 2/4885OPRD1 5/4885OPRK1 1/4885
US-20150133664-A1 CHEMICAL TRANSFORMATIONS OF (-)-CODEINE TO AFFORD DERIVATIVES OF CODEINE AND MORPHINE THEREOF OPRK1, OPRM1, OPRD1 OPRM1 2/4885OPRD1 3/4885OPRK1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.